Is a Gleason Score of 7 a Death Sentence?

A Gleason 7 result is not a death sentence. Most men diagnosed with it live for many years and never die of prostate cancer. It sits in the middle of the prostate cancer scale, more serious than the slowest-growing cancers but well short of the most aggressive ones. The two numbers that add up to 7 matter as much as the total, because one version of Gleason 7 behaves quite differently from the other.

What the Numbers on Your Report Mean

A pathologist looks at the cancer cells under a microscope and grades each area from 3 to 5. Higher numbers mean cells that look less like normal prostate tissue.¹ The two most common grades are then added together to give the Gleason score.² The pattern seen most is written first, so a score of 7 can be 3+4 or 4+3.³ A 3+4 tumor is mostly grade 3 with a smaller amount of grade 4. A 4+3 tumor is mostly the more aggressive grade 4.

That order is the quickest clue to which kind of 7 you have. Two men with the same total can have tumors that look and behave differently, which is why doctors ask for the split and not only the total.

Many reports now also list a Grade Group, a 1-to-5 scale built from the Gleason score.⁴ Gleason 3+4 is Grade Group 2, and Gleason 4+3 is Grade Group 3. The Grade Group line may appear instead of the Gleason score or beside it.

Gleason 6 is the lowest score now given, so 7 is the second step on the scale, not the middle of a 2-to-10 range. People often read 7 as “7 out of 10” and assume it is nearly the worst, but it is a step above the lowest, not near the top.

When you read your own report, look for both the total and the two numbers, for example “Gleason 3+4=7.” Reports often give the percentage of pattern 4, which shows how close a 3+4 is to a 4+3. If only “7” is written, ask your doctor which combination it is.

How Likely You Are to Survive Gleason 7

Ten years after prostate removal, 97% of men with 3+4 and 93% with 4+3 had not died of prostate cancer.⁵ Among Gleason 7 men who have surgery, more than half appear cured long term, except those whose cancer has spread through the prostate wall and reached the cut edge.⁶

These figures count only deaths from prostate cancer, not deaths from other causes. Your own odds also depend on your stage, PSA level, and margins, so ask your doctor to put your specific numbers into a risk calculator.

“Cured” has a particular meaning here. Doctors judge success by PSA, which should fall to nearly undetectable after the prostate is removed. If it stays undetectable year after year, the cancer is considered gone, though checks continue because late returns are possible.

In one long-running group of men, many of them older and not all treated with surgery, those with Gleason 7 lived an average of 10 years before dying of prostate cancer, against 5 years for scores of 8 to 10.⁷ That group was diagnosed decades ago, before modern scans and treatments, so today’s outlook is generally better.

The surgery figures also can’t be applied to everyone. The 10-year numbers come from men who had their prostates removed, and surgery is usually offered to men who are fit and expected to live long. Men who chose radiation or monitoring, or were older and sicker, may have different results, so these figures are a guide and not a promise. If you are considering a different treatment, ask what is known for men like you who chose it.

Age and other health matter too. Men 75 and older often have a life expectancy under 10 years from other causes, though healthy men in this age group may live considerably longer.⁸ For many older men, other illnesses are more likely than a Gleason 7 cancer to be the cause of death. It helps to ask whether your cancer is classed as favorable or unfavorable intermediate risk, and how your age and other conditions change the balance.

Why 4+3 Carries More Risk Than 3+4

Grade 4 cells look less like normal tissue and tend to grow and invade more readily. In 4+3 they make up most of the tumor, so there is simply more faster-growing material and a greater chance some has already escaped the prostate.

At surgery, cancer had grown beyond the prostate in about 38% of 3+4 cases and 53% of 4+3 cases.⁹ Within 5 years, the cancer progressed in about 15% of men with 3+4 and 40% of men with 4+3.¹⁰ Spread to other parts of the body developed in about 4% of men with 3+4 and about 11% with 4+3 over roughly 5 to 6 years.¹¹

“Grown beyond the prostate” usually means cancer has pushed into the outer layer of the gland or nearby tissue, not that it is in distant organs. Many men with this finding are still treated successfully, often with surgery followed by radiation if needed. It is different from spread to bones or lymph nodes, which is the much rarer outcome in the separate figures.

After surgery, doctors track PSA in the blood. A rise again, called biochemical recurrence on reports, is often the first sign cancer is back.¹² Five years after surgery, PSA had stayed undetectable in about 76% of men with 3+4 and 61% with 4+3.¹³ A rising PSA often leads to further treatment such as radiation.

After surgery, men with 4+3 were about three times as likely to die of prostate cancer as men with 3+4.¹⁴ In one large group of men, the risk of dying with 4+3 was similar to that of Gleason 8 to 10.¹⁵ So 4+3 is often treated more like a higher-risk cancer than like 3+4. Tripling a small risk still leaves a small risk, since ten-year cancer survival was still 93% for 4+3.

If your result is 4+3, ask whether you need imaging to check for spread before treatment, whether hormone therapy should be added to radiation, and whether active surveillance is off the table for you.

Other Findings That Change the Outlook

Some reports mention a “cribriform” pattern, grade 4 cells forming sheets with holes like a sieve.¹⁶ Men with Gleason 7 and this pattern were about 8 times as likely to have spread to other organs after surgery.¹⁷ In one group of 3+4 men, PSA came back in about 36% with cribriform or related patterns versus about 10% without.¹⁸

Cribriform glands are a form of grade 4, so a report can read 3+4 and still contain this pattern. Two men with the same Gleason score can therefore have different risk. It is one clue among several and not an automatic sign of poor outcome, but it pushes doctors toward more careful treatment and often rules out monitoring alone.

A “positive margin” means cancer reaches the edge of the tissue removed in surgery.¹⁹ The pathologist saw cancer cells touching the inked edge, so some may have been left behind. That does not mean cancer is definitely still present, and many men with this finding have a normal PSA afterward. When grade 4 cells were at the edge, 15-year cancer survival was 86%, versus 96 to 97% otherwise.²⁰ Because PSA is more likely to return, doctors watch it closely and sometimes recommend radiation after surgery. A small amount of grade 5, sometimes written as a “tertiary” pattern, makes PSA return more likely.²¹

Men with inherited changes in genes such as BRCA1, BRCA2, or ATM more often have Gleason 7 or higher cancers and tend to have shorter survival.²² Ask about genetic testing if close relatives had prostate, breast, ovarian, or pancreatic cancer. Gene results can affect family members’ screening too.

These details may sit in a comment section rather than the main line of your report. Look for words like cribriform, intraductal, margin, or tertiary grade. If none are mentioned, ask whether they were looked for.

Treatment Choices for Gleason 7

Surgery removes the whole prostate, and it also gives a full pathology exam that can refine the score and show whether cancer reached the edge. Radiation treats the prostate from outside the body, or sometimes with radioactive seeds placed inside it, without an operation. For many men with Gleason 7, the two have broadly comparable cancer control, so the choice often rests on health, age, and which side effects you would rather risk.

Surgery can cause leakage and erection problems, often improving over a year. Radiation can affect bowel and bladder, and its effects build slowly. Hormone therapy may cause hot flashes and fatigue.

Active surveillance means regular PSA tests, scans, and biopsies instead of immediate treatment.²³ For carefully selected middle-risk men, 5-year results were similar to those for lowest-risk men on surveillance.²⁴ By 10 to 15 years, spread is somewhat more common, though still uncommon.²⁵ Doctors still struggle to tell which 3+4 men can safely be monitored.²⁶

It is generally considered for 3+4 cancers where only a small share of the biopsy cores contain cancer and PSA is not high. A man with a cribriform pattern or a large amount of grade 4 is a poorer candidate. Even among 3+4 men the decision is individual, and doctors often want a fresh MRI and sometimes a repeat biopsy first.

Life on surveillance means PSA checks every few months and repeat biopsies or MRI. Treatment begins if the cancer shows signs of growing. Anxiety on surveillance did not depend on Gleason score.

For 4+3 or cancer found in half or more of biopsy cores, adding short-term hormone therapy to radiation raised 5-year control from about 82% to 93%.²⁷ For the more favorable cases, hormone therapy added almost nothing.²⁸ Men with 3+4 and limited cancer can often skip hormone therapy and its side effects.

Focal therapy treats only the part of the prostate with cancer, using heat, cold, or electric pulses.²⁹ Early results look good for cancer control and for keeping erections and bladder control.³⁰ Long-term results are not yet known, and in one small study recurrence-free rates fell from 90% at 5 years to 38% at 10.³¹

How Certain Is the Grade, and Tests That Sharpen It

Gleason grading depends on a pathologist’s judgment about how a pattern looks, and neighboring patterns can look alike. The line between a 3 and a 4 is where disagreement is most common, and that line separates 6 from 7 and 3+4 from 4+3. When experts reviewed the same slides, about 13% of Gleason 7 samples were scored 6 by some readers, and 18% of 6s were scored 7.³² Disagreement is more common for borderline cases than for tumors that are clearly very low or very high grade.

Asking for a second pathologist’s review is reasonable before major decisions. Your doctor can send slides to a specialist center, which usually takes one to two weeks and rarely delays treatment harmfully for Gleason 7. A second reader may confirm the score, and for most men that is what happens. Sometimes the review moves a result across a line, such as from 3+4 to 4+3 or from 6 to 7, and that can change whether surveillance is reasonable. It uses the same slides, so it needs no new biopsy. Computer tools helped general pathologists grade more consistently.³³

Biopsies aimed by MRI found risky patterns like cribriform more often than standard biopsies.³⁴ Gene tests on biopsy tissue, such as Decipher, Prolaris, and Oncotype DX, estimate how aggressive a cancer is.³⁵ Their long-term benefit and cost-effectiveness are still being studied.³⁶

Extra tests are most worth asking about before choosing active surveillance for 3+4, or if your result sits near the 3+4 versus 4+3 line. Ask whether insurance covers genomic testing.